Wealthfront Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.83M	Sell	11,587 -6,667	-37%	-$2.27M	0.01%	475
2025 Q4	$7.26M	Buy	18,254 +4,834	+36%	+$2.14M	0.02%	311
2025 Q3	$6.12M	Buy	13,420 +1,336	+11%	+$544K	0.01%	346
2025 Q2	$3.94M	Buy	12,084 +3,363	+39%	+$931K	0.01%	425
2025 Q1	$2.35M	Sell	8,721 -3,899	-31%	-$1M	0.01%	500
2024 Q4	$2.97M	Buy	12,620 +4,324	+52%	+$1.14M	0.01%	434
2024 Q3	$2.28M	Buy	8,296 +200	+2%	+$52.1K	0.01%	473
2024 Q2	$1.97M	Buy	8,096 +6	+0.1%	+$947	0.01%	484
2024 Q1	$1.21M	Sell	8,090 -3,495	-30%	-$583K	﹤0.01%	578
2023 Q4	$2.22M	Sell	11,585 -772	-6%	-$131K	0.01%	440
2023 Q3	$2.19M	Sell	12,357 -15,289	-55%	-$2.92M	0.01%	405
2023 Q2	$5.25M	Sell	27,646 -6,667	-19%	-$1.32M	0.02%	205
2023 Q1	$6.87M	Buy	34,313 +1,727	+5%	+$363K	0.03%	161
2022 Q4	$7.74M	Buy	32,586 +14,210	+77%	+$3.03M	0.04%	141
2022 Q3	$3.68M	Buy	18,376 +4,258	+30%	+$812K	0.02%	237
2022 Q2	$2.06M	Buy	14,118 +1,273	+10%	+$181K	0.01%	375
2022 Q1	$2.1M	Buy	12,845 +11,526	+874%	+$1.76M	0.01%	391
2021 Q4	$224K	Buy	+1,319	New	+$245K	﹤0.01%	731